DTB

Pandey research group: Cancer epigenetics

GBMs are the most prevalent and aggressive malignant tumor of the central nervous system. With a median overall survival of only one year, GBM patients have a particularly poor prognosis. The standard treatment for GBM patients is surgical resection, radiotherapy, and chemotherapy with DNA-alkylating agents, and unfortunately current treatments only extend overall survival by a few months, thereby highlighting a clear need for novel therapeutic strategies to target this disease.

Our research program focuses on identification and targeting of novel transcriptional and epigenetic requirements aka addictions, in cancer and as a cancer model, we work with tumors of central nervous systems, in particular Glioblastoma (GBM). Over the years, we have identified several druggable transcriptional and epigenetic dependencies to target glioblastoma and projects in my group involve further mechanistic characterization and validation of these requirements.